The clinical translation of a near-infrared fluorophore for fluorescence guided surgery: SGM-101 from the lab to a phase III trial

摘要

Near-infrared (NIR) fluorescence imaging is a promising intraoperative technique for real-time visualization of tumortissue during surgery. The process of clinical translation of novel fluorescent agents is an essential part in the evolution ofNIR fluorescence guided surgery. Poor visualization of tumors during surgery is one of the major challenges surgeonsoften face in oncologic patients, mainly due to the improved neo-adjuvant treatment patients receive. In these cases, NIRfluorescence imaging with the use of tumor-targeted fluorescent agents can play an essential role and help provide betteroncologic results or patient outcomes. However, before this technique can be implemented in standard of care, optimaltumor-targeted fluorescent agents need to be developed and novel fluorescent agents need to undergo a successful processof clinical translation. Here we describe the clinical translation of SGM-101, a fluorescent anti-CEA monoclonal antibody.